Cargando…

Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings

Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Alborghetti, Marika, Bianchini, Edoardo, De Carolis, Lanfranco, Galli, Silvia, Pontieri, Francesco E., Rinaldi, Domiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479837/
https://www.ncbi.nlm.nih.gov/pubmed/37488838
http://dx.doi.org/10.4103/1673-5374.375299
_version_ 1785101677527826432
author Alborghetti, Marika
Bianchini, Edoardo
De Carolis, Lanfranco
Galli, Silvia
Pontieri, Francesco E.
Rinaldi, Domiziana
author_facet Alborghetti, Marika
Bianchini, Edoardo
De Carolis, Lanfranco
Galli, Silvia
Pontieri, Francesco E.
Rinaldi, Domiziana
author_sort Alborghetti, Marika
collection PubMed
description Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson’s disease, such as mood deflection, cognitive impairment, sleep disturbances, and fatigue. Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson’s disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors, particularly glial cell line-derived neurotrophic factor, which support dopaminergic neurons. Besides, safinamide may interfere with neurodegenerative mechanisms, counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity. Due to the dual mechanism of action, the new generation of type-B monoamine oxidase inhibitors, including safinamide, is gaining interest in other neurological pathologies, and many supporting preclinical studies are now available. The potential fields of application concern epilepsy, Duchenne muscular dystrophy, multiple sclerosis, and above all, ischemic brain injury. The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline, rasagiline, and safinamide in Parkinson’s disease and beyond, focusing on possible future therapeutic applications.
format Online
Article
Text
id pubmed-10479837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104798372023-09-06 Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings Alborghetti, Marika Bianchini, Edoardo De Carolis, Lanfranco Galli, Silvia Pontieri, Francesco E. Rinaldi, Domiziana Neural Regen Res Review Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson’s disease, such as mood deflection, cognitive impairment, sleep disturbances, and fatigue. Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson’s disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors, particularly glial cell line-derived neurotrophic factor, which support dopaminergic neurons. Besides, safinamide may interfere with neurodegenerative mechanisms, counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity. Due to the dual mechanism of action, the new generation of type-B monoamine oxidase inhibitors, including safinamide, is gaining interest in other neurological pathologies, and many supporting preclinical studies are now available. The potential fields of application concern epilepsy, Duchenne muscular dystrophy, multiple sclerosis, and above all, ischemic brain injury. The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline, rasagiline, and safinamide in Parkinson’s disease and beyond, focusing on possible future therapeutic applications. Wolters Kluwer - Medknow 2023-05-31 /pmc/articles/PMC10479837/ /pubmed/37488838 http://dx.doi.org/10.4103/1673-5374.375299 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review
Alborghetti, Marika
Bianchini, Edoardo
De Carolis, Lanfranco
Galli, Silvia
Pontieri, Francesco E.
Rinaldi, Domiziana
Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
title Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
title_full Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
title_fullStr Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
title_full_unstemmed Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
title_short Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
title_sort type-b monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479837/
https://www.ncbi.nlm.nih.gov/pubmed/37488838
http://dx.doi.org/10.4103/1673-5374.375299
work_keys_str_mv AT alborghettimarika typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings
AT bianchiniedoardo typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings
AT decarolislanfranco typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings
AT gallisilvia typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings
AT pontierifrancescoe typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings
AT rinaldidomiziana typebmonoamineoxidaseinhibitorsinneurologicaldiseasesclinicalapplicationsbasedonpreclinicalfindings